Oncology Fellows
Vol.18-No.1
Volume: 18
Issue: 1
Vol. 17/No. 3
Vol.17/No.4
Volume: 17
Issue: 4
Vol. 17/No. 2
Volume: 17
Issue: 2
Vol. 17/No. 1
Volume: 17
Issue: 1
Vol. 16/No. 4
Volume: 16
Issue: 4
Vol. 16/No. 3
Volume: 16
Issue: 3
Vol. 16/No. 2
Volume: 16
Issue: 2
Vol. 16/No. 1
Volume: 16
Issue: 1
Vol. 15/No. 4
Volume: 15
Issue: 4
Vol. 15/No. 3
Volume: 15
Vol. 15/No. 2
Volume: 14
Vol. 15/No. 1
Volume: 15
Issue: 1
Vol. 14/No. 4
Volume: 14
Issue: 4
Vol. 14/No. 3
Volume: 14
Issue: 3
Vol. 14/No. 2
Volume: 14
Issue: 2
Vol. 14/No. 1
Volume: 14
Issue: 1
Vol. 13/No. 4
Volume: 13
Issue: 4
Vol. 13/No. 3
Volume: 13
Issue: 3
Vol. 13/No. 2
Volume: 13
Issue: 2
Vol. 13/No. 1
Volume: 13
Issue: 1
December 2020
Volume: 12
Issue: 4
September 2020
Volume: 1
Issue: 1
June 2020
Volume: 12
Issue: 2
March 2020
Volume: 12
Issue: 1
December 2019
Volume: 11
Issue: 3
September 2019
Volume: 11
Issue: 3
March 2019
Volume: 11
Issue: 1
June 2019
Volume: 11
Issue: 2
December 2018
Volume: 10
Issue: 4
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5